Myriad Genetics Announces an Assay that Identifies Patients for Olaparib Treatment

Myriad Genetics Announces an Assay that Identifies Patients for Olaparib Treatment


Salt Lake City-based Myriad Genetics, Inc. announced that its BRACAnalysis CDx test accurately identifies patients with ovarian cancer for a second-line treatment with olaparib. The announcement came as a result of a clinical study finding that the Myriad diagnostic device accurately identifies patients for olaparib treatment.



from Biotech News